title: Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.
abstract: The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the treatment landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T, radium, and selected emerging agents are presented. A distinct focus on the utilization of enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and Drug Administration approval, as well as patient-focused perspectives and clinical implications are discussed herein.
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA.
authors.forename: Nihar K
authors.initials: NK
authors.lastname: Patel
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA.
authors.forename: Antoine
authors.initials: A
authors.lastname: Finianos
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA.
authors.forename: Kristen D
authors.initials: KD
authors.lastname: Whitaker
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA.
authors.forename: Jeanny B
authors.initials: JB
authors.lastname: Aragon-Ching
keywords: enzalutamide; metastatic castration-resistant prostate cancer; systemic therapies